Skip to main content

Market Overview

Recap: Ironwood Pharmaceuticals Q1 Earnings



Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) remained unaffected after the company reported Q1 results.

Quarterly Results

Earnings per share were up 500.00% over the past year to $0.24, which beat the estimate of $0.21.

Revenue of $88,845,000 higher by 11.14% from the same period last year, which missed the estimate of $95,200,000.

Looking Ahead

The upcoming fiscal year's revenue expected to be between $370,000,000 and $385,000,000.

Conference Call Details

Date: May 06, 2021

Time: 08:30 AM

ET Webcast URL:

Price Action

Company's 52-week high was at $12.55

52-week low: $8.63

Price action over last quarter: Up 16.20%

Company Description

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.


Related Articles (IRWD)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at